Solid Reports Efficacy & Safety Data from Ongoing IGNITE DMD Clinical Trial &...
Solid Biosciences has provided a safety and efficacy update on the ongoing IGNITE DMD phase I/II clinical study of SGT-001 microdystrophin gene therapy in patients with Duchenne. Upcoming Webinar: Join...
View ArticleWATCH: Solid Biosciences Presents Safety & Efficacy Update (Webinar Recording)
On March 16, 2021, Solid Biosciences joined PPMD for a webinar to provide a safety and efficacy update on the ongoing IGNITE DMD phase I/II clinical study of SGT-001 microdystrophin gene therapy in...
View ArticleClik here to view.
Solid Provides IGNITE DMD Phase I/II Clinical Trial and Pipeline Update
Solid Biosciences has shared an update with the community this morning, including a dosing update in the IGNITE DMD Phase I/II clinical trial, promising long-term biopsy data from prior patients dosed...
View ArticleSolid provides updates on IGNITE DMD and SGT-003, next generation gene...
Solid Biosciences has shared an update with the community on dosing as part of the IGNITE DMD Phase I/II clinical trial, developments for next generation gene therapy pipeline initiative SGT-003 and...
View ArticleRecap: Recent Research Updates
Welcome to FALL Time flies! Over the past few months, we have seen a number of announcements regarding drug development, changes to clinical trials, and new trials opening or on the horizon. For many,...
View ArticleSolid Provides Updates on IGNITE DMD Study and SGT-003 Pre-Clinical Data
Solid Biosciences has shared an update from IGNITE DMD, an ongoing Phase I/II clinical trial evaluating its gene therapy candidate SGT-001 in participants with Duchenne, as well as developments for the...
View ArticleSolid Biosciences Reports 2-Year Efficacy and Safety Data from Ongoing Phase...
Solid Biosciences has shared an update from IGNITE DMD, an ongoing Phase I/II clinical trial evaluating its gene therapy candidate SGT-001 in participants with Duchenne. In the announcement, Solid...
View ArticleSolid Biosciences Shares Update on Duchenne Gene Therapy Pipeline Programs
Today Solid Bio shared an update on their gene therapy programs for SGT-001 and SGT-003. SGT-001 is Solid’s AAV9 microdystrophin gene therapy investigational product that is currently being evaluated...
View ArticleSolid Biosciences Acquires AavantiBio & Shares Update on Duchenne Gene...
Today Solid Biosciences shared an update with the Duchenne community regarding their strategic development. Solid announced they have acquired AavantiBio, a gene therapy company with a focus on rare...
View ArticleSolid Biosciences Announces Completion of AavantiBio Acquisition & Update on...
Today Solid Biosciences shared an update with the Duchenne community regarding their strategic development. Solid announced they have completed the acquisition of AavantiBio, a gene therapy company....
View Article
